grant

Longitudinal Multiparametric Magnetic Resonance Imaging of Outbred Rats with Variable Vulnerability to the Development of Oxycodone Addiction-like Behaviors

Organization UNIVERSITY OF CALIFORNIA, SAN DIEGOLocation LA JOLLA, UNITED STATESPosted 1 Mar 2026Deadline 28 Feb 2027
NIHUS FederalResearch GrantFY2026AMAC-1AMAC1AbstinenceAcuteAddressAgeAnatomic SitesAnatomic structuresAnatomyAnimalsBehaviorBehavioralBerryBrainBrain DiseasesBrain DisordersBrain Nervous SystemBrain imagingCCL18CCL18 geneCKb7CausalityCell BodyCellsChronicClassificationCommon Rat StrainsComplementComplement ProteinsComplexDC-CK1DCCK1DWI (diffusion weighted imaging)DWI-MRIDataData SetDevelopmentDifferences between sexesDiffers between sexesDiffusion MRIDiffusion Magnetic Resonance ImagingDiffusion Weighted MRIDiffusion weighted imagingDiffusion-weighted Magnetic Resonance ImagingDihydrohydroxycodeinoneDiseaseDisorderEmotionalEncephalonEncephalon DiseasesEnvironmentEtiologyExhibitsExposure toFemaleFollow-Up StudiesFunctional MRIFunctional Magnetic Resonance ImagingFundingGWA studyGWASGenerationsGeneticGenetic HeterogeneityGenomeGenomicsGenotypeGoalsHeterogeneityHumanImageIndividualIndividual DifferencesIntakeIntracranial CNS DisordersIntracranial Central Nervous System DisordersIntravenousInvestigationMIP-4MR ImagingMR TomographyMRIMRIsMagnetic Resonance ImagingMeasurementMeasuresMedical Imaging, Magnetic Resonance / Nuclear Magnetic ResonanceMentorshipMicroscopicModelingModern ManNIDANMR ImagingNMR TomographyNational Institute of Drug AbuseNational Institute on Drug AbuseNatureNeurosciencesNuclear Magnetic Resonance ImagingOpiatesOpioidOxycodeinonOxycodoneOxycodone SROxycontinPARCPainPainfulPharmaceutical AgentPharmaceuticalsPharmacologic SubstancePharmacological SubstancePhenotypePopulationPopulation HeterogeneityPredispositionPreventionProtocolProtocols documentationPublic HealthRatRats MammalsRattusRelapseResearchResearch ResourcesResourcesRewardsRodentRodent ModelRodentiaRodents MammalsRoxicodoneSCYA18Sample SizeScientistSelf AdministeredSelf AdministrationSeveritiesSex DifferencesSexual differencesSourceSpectroscopySpectrum AnalysesSpectrum AnalysisStandardizationStructureSusceptibilitySystematicsTranslatingTranslationsVulnerable PopulationsWithdrawalWorkZeugmatographyaddictionaddictive disorderagesbiobankbiorepositorybrain visualizationcausationclinical relevanceclinically relevantcomplementationdMRIdevelopmentaldiffusion tensor imagingdisabilitydisease causationdiverse populationsdrug metabolismexecutive controlexecutive functionfMRIfollow-up research studyfollow-up surveygenome wide associationgenome wide association scangenome wide association studygenomewide association scangenomewide association studyheterogeneous populationhuman modelimagingimaging studyimprovedincentive salienceindividual heterogeneityindividual variabilityindividual variationindividualized strategiesinsightlongitudinal imagingmodel of humanneural adaptationneuroadaptationopiate consumptionopiate drug useopiate intakeopiate useopiate use disorderopioid consumptionopioid drug useopioid intakeopioid useopioid use disorderoxycodone self-administrationpersonalization of treatmentpersonalized medicinepersonalized strategiespersonalized therapypersonalized treatmentpharmaceuticalpopulation diversitypre-clinicalpre-clinical imagingpreclinicalpreclinical imagingpreventpreventingresilienceresilientresponseself-administer oxycodoneserial imagingsex based differencessex-dependent differencessex-related differencessex-specific differencesstudy with follow-uptranslationtreatment strategyvulnerable groupvulnerable individualvulnerable peoplewhole genome association analysiswhole genome association study
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

PROJECT SUMMARY/ABSTRACT
Advancements in neuroscience, including magnetic resonance imaging (MRI), have significantly improved our

understanding of opioid use disorder (OUD) and brain function, yet due to the heterogeneity in the disorder and

complexity of the brain, controlled comprehensive approaches in heterogeneous populations are a necessity to

characterize individual variability. Here, longitudinal multi-parametric MRI is proposed to assess brain features

associated with OUD in genetically heterogeneous stock rats sourced from the NIDA-funded Rat Oxycodone

Biobank (U01DA051937), which provides rats with fully characterized genome and addiction-like behaviors,

going through a state-of-the-art pipeline with escalation of oxycodone intake following extended access to

intravenous oxycodone self-administration.

Leveraging features from structural, diffusion, and functional MRI, our investigation seeks to capture the

individual differences in the brain, at baseline before oxycodone exposure (Aim 1: pre-existing), and following

the oxycodone extended self-administration paradigm during acute withdrawal (12 h) (Aim 2: oxycodone-

induced), within the same rats that show vulnerability or resilience to developing oxycodone addiction-like

behaviors. We hypothesize that there will be an interaction between the results from both aims.

The I/START R03 proposal will allow for the introduction of MRI imaging into the PARC research environment,

as a for the PI new, clinically relevant approach, which will complement her current preclinical work with single-

cell whole-brain imaging and simplify the translation of the findings for human applications. The collaborative

pilot with the Rat Oxycodone Biobank thus aims to set up the basis for larger follow-up studies that will allow

for the generation of a heterogeneous, high-quality imaging dataset that will be made publicly available and

complement already extensive genomic and behavioral characterization in the same animals. This data will

significantly contribute to our understanding of the variable impact of opioids on the brain and individual

differences in vulnerability to OUD, providing a unique opportunity to disentangle pre-existing differences from

those that are a consequence of exposure to oxycodone. Ultimately, this research seeks to pave the way for

improved prevention and personalized treatment strategies, thereby reducing illness and disability associated

with OUD.

Grant Number: 1R03DA064666-01
NIH Institute/Center: NIH

Principal Investigator: Lieselot Carrette

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →